Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block

NCT07263165 | Not Yet Recruiting

• 1 other identifier: External Ob. intercostal block
• Study Type: interventional
• Target: 54
• Locations: 0 countries
• Sites: N/A

Brief Summary

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery.

Conditions

Opioid Consumption, Postoperative

Keywords

dexmedetomidine; external oblique intercostal block

Outcome Measures

Primary Outcomes (1)

• Total Postoperative Opioid Consumption (mg of morphine equivalents)

  To evaluate the effect of adding dexmedetomidine to bupivacaine on total opioid consumption within the first 24 hours after upper abdominal cancer surgery.

  24 hours postoperative.

Secondary Outcomes (5)

• Postoperative Pain Intensity Using the Visual Analog Scale (VAS 0-10)

  2, 4, 6, 12, 18, and 24 hours postoperative.

• Time to First Request for Rescue Analgesia.

  24 hour postoperative

• Number of Participants with Adverse Effects

  first 2 hours postoperative.

• patient satisfaction score

  1 hour postoperative

• Block-related complications.

  intraoperative and 24 postoperative

Study Arms (2)

Dexmedetomidine + Bupivacaine

EXPERIMENTAL

Participants will receive an ultrasound-guided external oblique intercostal plane block using 20 mL of 0.25% bupivacaine combined with dexmedetomidine (0.5 µg/kg) administered as a single-shot injection.

Drug: Dexmedetomidine

Bupivicaine

ACTIVE COMPARATOR

Participants will receive an ultrasound-guided external oblique intercostal plane block using 20 mL of 0.25% bupivacaine administered as a single-shot injection without any adjuvant.

Drug: Dexmedetomidine

Interventions

Dexmedetomidine DRUG

Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block

Bupivicaine; Dexmedetomidine + Bupivacaine

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18-70 years scheduled for elective upper abdominal cancer surgery (e.g., gastrectomy, hepatectomy, pancreatectomy).
• American Society of Anesthesiologists (ASA) physical status I-III.
• Body mass index (BMI) between 18-35 kg/m².

You may not qualify if:

• Patient refusal.
• Allergy to local anesthetics or dexmedetomidine.
• Coagulopathy (INR \>1.5, platelet count \<100,000/mm³).
• Infection at the injection site.
• Severe cardiopulmonary, renal, or hepatic dysfunction.
• Chronic opioid use (\>30 mg morphine equivalents daily for \>3 months).
• Pregnancy or lactation.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Central Study Contacts

Mohamed i Shaker

CONTACT

01012248619; aboiprahem1997@gmail.com

Moaaz M Tohamy

CONTACT

moaaz@aun.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Anesthesia Resident

Study Record Dates

• First Submitted: November 16, 2025
• First Posted: December 4, 2025
• Study Start: December 15, 2025
• Primary Completion: February 15, 2026
• Study Completion (Estimated): December 15, 2027
• Last Updated: December 4, 2025

Record last verified: 2025-10